MPI Research, the largest single-site preclinical Contract Research Organization (CRO) worldwide, is pleased to announce that its Quantitative Whole-Body Autoradiography (QWBA) laboratory has achieved full GLP validation. Ms. Andrea Knapp, MPI Research scientist, manages the QWBA laboratory. Mr. Brian Knapp, associate Study Director, provides appropriate QWBA study design and interpretation. Together, they have nearly 25 years of QWBA experience.
QWBA is a high-resolution tissue distribution assessment commonly used in preclinical drug development, which typically uses isotopes with long half-lives that can be easily incorporated into target compounds. At MPI Research, QWBA also incorporates short-lived isotopes for the development of biologics. The use of short-lived isotopes allows QWBA to be combined with multiple imaging platforms such as PET and SPECT within a single study design, maximizing data generation and reducing animal usage in preclinical research.
Tina Rogers, PhD, MBA, DABT, Chief Scientific Officer and Vice President of Strategic Accounts at MPI Research, states, “Our Sponsors are pleased that MPI Research can now offer a fully GLP-validated QWBA laboratory. As we optimize isotopes to meet the needs of our Sponsors, we are becoming known as a premier provider of QWBA services. Having GLP status significantly adds value to the scope of services provided by MPI Research to the global marketplace.”
Register for an educational webinar on Thursday, November 29, 2011, 1 to 2 pm EST, presented by MPI Research QWBA experts Andrea Knapp and Brian Knapp. During this webinar they will explore the novel application of short-lived isotopes as QWBA is incorporated into the drug development paradigm